Medical use of cannabis for glaucoma

(October 2018)

Background

The clinical utility of cannabis (sometimes referred to as marijuana or marihuana) for the treatment of glaucoma is limited by the inability to separate the potential clinical action from the undesirable neuropsychological and behavioural effects. The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of glaucoma due to the short duration of action, the incidence of undesirable psychotropic and other systemic side effects and the absence of scientific evidence showing a beneficial effect on the course of the disease. This is in contrast to other more effective and less harmful medical, laser and surgical modalities for the treatment of glaucoma.

Access Details

Read the full policy statement from the Canadian Ophthalmological Society (COS) and the Canadian Glaucoma Society (CGS).

Related Resources

Immediate Sequential Bilateral Cataract Surgery (ISBCS) COVID-19 Considerations

December, 2020 This document, prepared by ACUPO and endorsed by...

More Info

CMA Physician Wellness Hub

As a physician, when you’re well, everyone benefits. Healthy and...

More Info

OICS Guidelines for the Cleaning and Sterilization of Intraocular Surgical Instruments

December, 2020 Guidelines for the Cleaning and Sterilization of Intraocular...

More Info

Half of all #glaucoma patients are unaware that they have the condition. That’s why eye exams are so important! bit.ly/12lZigR #glaucoma #eyehealth #ophthalmology #GlaucomaAwarenessMonth

Yesterday from Can Ophthal Society's Twitter via Hootsuite Inc.

Can Ophthal Society's Twitter via Twitter Web Client